The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Dennis A. Revicki

Center for Health Outcome Research

MEDTAP International

Inc., Bethesda

MD 20814



Name/email consistency: high



  • Center for Health Outcome Research, MEDTAP International, Inc., Bethesda, MD 20814, USA. 1998 - 2005
  • MEDTAP International Inc., Bethesda, USA. 1999 - 2000
  • MEDTAP International, Inc., 7101 Wisconsin Avenue, Suite 600, USA. 2000
  • MEDTAP International, Arlington, Virginia 22201, USA. 1996 - 1999


  1. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. Revicki, D.A., Hirschfeld, R.M., Ahearn, E.P., Weisler, R.H., Palmer, C., Keck, P.E. J. Affect. Disord (2005) [Pubmed]
  2. Patient assessment of treatment satisfaction: methods and practical issues. Revicki, D.A. Gut (2004) [Pubmed]
  3. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Revicki, D.A., Rentz, A.M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N.J., Tack, J. Qual. Life. Res (2004) [Pubmed]
  4. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Revicki, D.A., Rentz, A.M., Tack, J., Stanghellini, V., Talley, N.J., Kahrilas, P., De La Loge, C., Trudeau, E., Dubois, D. Clin. Gastroenterol. Hepatol. (2004) [Pubmed]
  5. Cost-effectiveness and HRQOL outcomes of divalproex sodium (Depakote(R)) in bipolar disorder. Revicki, D.A. Expert. Rev. Pharmacoecon. Outcomes. Res (2004) [Pubmed]
  6. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, D.A., Paramore, L.C., Sommerville, K.W., Swann, A.C., Zajecka, J.M. J. Clin. Psychiatry (2003) [Pubmed]
  7. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Revicki, D.A., Rentz, A.M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N.J., Tack, J. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  8. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Revicki, D.A., Zodet, M.W., Joshua-Gotlib, S., Levine, D., Crawley, J.A. Health. Qual. Life. Outcomes (2003) [Pubmed]
  9. Imputing physical health status scores missing owing to mortality: results of a simulation comparing multiple techniques. Revicki, D.A., Gold, K., Buckman, D., Chan, K., Kallich, J.D., Woolley, J.M. Med. Care (2001) [Pubmed]
  10. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Revicki, D.A. Curr. Opin. Investig. Drugs (2001) [Pubmed]
  11. The new atypical antipsychotics: a review of pharmacoeconomic studies. Revicki, D.A. Expert. Opin. Pharmacother (2000) [Pubmed]
  12. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Revicki, D.A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, N.K., Rothman, M. Qual. Life. Res (2000) [Pubmed]
  13. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. Revicki, D.A. J. Clin. Psychiatry (1999) [Pubmed]
  14. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Revicki, D.A. Schizophr. Res. (1999) [Pubmed]
  15. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Revicki, D.A., Moyle, G., Stellbrink, H.J., Barker, C. AIDS (1999) [Pubmed]
  16. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Revicki, D.A., Frank, L. Pharmacoeconomics (1999) [Pubmed]
  17. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Revicki, D.A., Crawley, J.A., Zodet, M.W., Levine, D.S., Joelsson, B.O. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  18. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Revicki, D.A., Swartz, C., Wu, A.W., Haubrich, R., Collier, A.C. Antivir. Ther. (Lond.) (1999) [Pubmed]
  19. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Revicki, D.A., Leidy, N.K., Brennan-Diemer, F., Thompson, C., Togias, A. Qual. Life. Res (1998) [Pubmed]
  20. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. Revicki, D.A., Wood, M. J. Affect. Disord (1998) [Pubmed]
  21. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Revicki, D.A., Leidy, N.K., Brennan-Diemer, F., Sorensen, S., Togias, A. Chest (1998) [Pubmed]
  22. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Revicki, D.A., Sorensen, S., Maton, P.N., Orlando, R.C. Dig. Dis (1998) [Pubmed]
  23. Work-related stress and psychological distress in emergency medical technicians. Revicki, D.A., Gershon, R.R. J. Occup. Health. Psychol (1996) [Pubmed]
WikiGenes - Universities